Last reviewed · How we verify
NCT06205797
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
Phase 3 trial testing HU-045 in Glabellar Lines in 312 participants. Currently enrolling.
30 November 2024
Quick facts
| Lead sponsor | Huons Biopharma |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 312 |
| Start date | 20 June 2024 |
| Primary completion | 30 November 2024 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
Conditions studied
- Glabellar Lines — all drugs for Glabellar Lines →
Sponsor
Huons Biopharma — full company profile →
Who can join
Adults 19 to 65, any sex, with Glabellar Lines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06205797
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HU-045
Trials testing the same drug.
- NCT05298449 — Phase 2 of HU-045 in Glabellar Lines · Phase 2 · completed
Other Huons Biopharma trials
Trials by the same sponsor.
- NCT05964257 — To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06205797 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huons Biopharma
- Last refreshed: 3 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205797.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing